Abraham earned his Ph.D. in 1976 from the Mt. Sinai School of Medicine in New York City. He spent his postdoctoral fellowship at The Rockefeller University, where he discovered and isolated the rat and human heme oxygenase gene responsible for the over-production of bilirubin in newborn infants, which manifests as jaundice. In early 1982, he developed inhibitors of heme oxygenase for the prevention of jaundice with his mentor Dr. A. Kappas, former vice president of The Rockefeller University and physician-in-chief. In 1977, he became an associate scientist at New York Medical College in New York. He initiated the college’s first program project on heme oxygenase in 1985. During his time there, he was promoted to the rank of professor with tenure in medicine in 1993. Abraham was named a visiting professor of medicine at New York University in 1993, at which time he also continued his affiliation with The Rockefeller University as a visiting scientist. In 1996, he re-joined New York Medical College as a professor in the departments of pharmacology and medicine and also served as director of the stem cell and gene therapy program. In 2009, while maintaining affiliations with both the New York Medical College and The Rockefeller University, Abraham was named chairman and professor of the department of physiology and pharmacology at The University of Toledo College of Medicine. During his tenure as chair of the department at Toledo, NIH and pharmaceutical support increased from $2.5 million to more than $7 million in less than four years. He is also affiliated with the University of Catania in Italy.
All accepted abstracts will be published in respective Allied Academies Journals.
Abstracts will be provided with Digital Object Identifier by
